Terms ending in 2039
Every in-force patent on Pfizer Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,661,438 | Purification of Antibody Drug Conjugates Using a Sodium Phosphate Gradient In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,662,204 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,987,634 | Antibodies Specific for CD70 and Their Uses In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,590,115 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US D1,014,246 | External Medication Packaging In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 12,152,081 | Chimeric Antigen Receptors Targeting CD70 In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US 12,522,649 | Antibody Purification In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US D1,017,017 | Pill In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,538,542 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,968,242 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) In force · High confidence | Pfizer Inc. | In force | High confidence | |
| 51 more term ends in 2039 · Pro | |||||
10 of 61 patents shown. Soonest term end first, then patent number.
Pro members see all 61.
60 of these are in force and held by Pfizer Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.